Decolonization of Pathogenic Enterobacteria, Such as E. Coli And/or Klebsiella Pneumoniae, from the Gut Using Strains of E. Coli

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes the use of specific probiotic strains of E. coli, alone or in combination with strains of Klebsiella oxytoca or Klebsiella michiganensis, to decolonize pathogenic and multidrug resistant (MDR) Enterobacteriaceae—such as E. coli, Klebsiella pneumoniae—as well as Enterococci and Acinetobacter from the gut. The approach can be applied preventively (to stop pathogenic colonization after antibiotic use or microbiome disruption) or therapeutically (to eradicate existing infections with pathogenic or drug-resistant bacteria). By selecting and using certain commensal bacterial strains that are shown to outcompete or displace harmful bacteria, the invention offers an alternative to antibiotics and fecal microbiota transplantation for restoring gut health and preventing infection.

Use CasesContent extracted from patent full text and abstract with AI.

• Preventing or treating gut colonization with multidrug resistant E. coli, Klebsiella pneumoniae, Enterococci, and Acinetobacter in humans or animals.
• Restoring healthy gut microbiota after antibiotic treatment or when gut dysbiosis has occurred.
• Reducing the risk of bloodstream infections, sepsis, and organ invasion (liver, spleen, lymph nodes) in immunocompromised patients (e.g., post stem cell transplant).
• Preventing recurrent infections or gut colonization in healthcare or veterinary settings.
• Formulating new medical probiotics, oral supplements, or pharmaceutical compositions to suppress MDR gut pathogens.
• Prophylactic administration to at-risk populations (hospitalized patients, elderly, livestock) to reduce pathogen transmission.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a non-antibiotic based strategy to eliminate or prevent colonization by multi-drug resistant bacteria, helping to combat antibiotic resistance.
• Specific strain combinations demonstrated a synergistic effect, increasing efficacy and broadening the spectrum of pathogens targeted.
• Safer and more defined than fecal microbiota transplantation, lowering the risk of transmitting unknown or harmful microorganisms.
• Can be used both as a preventive and therapeutic measure.
• Restores or maintains natural colonization resistance, supporting a healthy gut microbiome and reducing the risk of infection.
• Applicable to both human and veterinary medicine, potentially reducing MDR pathogens in food animals and limiting zoonotic transmission.
• Potentially reduces hospital costs and complications associated with MDR infections and recurrent gut disturbances.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to probiotic bacteria of the species E. coli, in particular in combination with bacteria of the species Klebsiella oxytoca, that are used for a decolonization of pathogenic and/or multi drug resistant (MDR) Enterobacteria, such as pathogenic E. coli and/or Klebsiella pneumoniae (K. pneumoniae), Enterococci and/or Acinetobacter, from the gut of a subject. The decolonization can both be therapeutic, i.e. after colonization of the gut by the pathogenic and/or multi-resistant pathogen(s), or as a preventive measure before a re-colonization of the gut, as required after antibiotic treatment or treatment-induced dysbiosis.